Roche expects deal will allow it to concentrate Korean activities on its specialty care franchise.
Singapore-based pharmaceutical commercialization services firm Invida inked a partnership with Roche to commercialize the latter’s primary care portfolio in Korea. Under terms of the deal Invida will manage all the marketing and sales activities for relevant Roche products including Xenical® and Roaccutane® and CNS portfolio products such as Modapar®, Rivotril®, and Valium.
The firm says taking on responsibility for the primary care franchise means Roche will be able to focus on its specialty care portfolio in Korea. “Our partnership with Invida is critical to ensure our success in further penetrating the Korean market,” remarks Svend Petersen, GM of Roche Korea. “We will be able to gain rapid market access for these products. This alliance will support our business goals by allowing us to shift resources and focus on our specialty care portfolio.”
The agreement will also provide Invida with a roadmap for future partnerships of this kind in Korea and the Asia Pacific region, notes John A. Graham, CEO. Less than two weeks ago the firm expanded its existing agreement with Sinclair Pharma by adding India to the 11 Asia Pacific markets in which Invida already has exclusive rights to market Sinclair’s dermatology and woundcare brands.
Invida specializes in commercializing drugs throughout the Asia Pacific region and offers partnering expertise spanning regulatory approval and product launch. With over 4,000 employees throughout the region the firm manages a portfolio of proprietary healthcare brands as well as licensed products from biotech and big pharma.
It claims Asia Pacific currently accounts for $50 billion in pharmaceutical sales annually, representing 10% of the worldwide market. The most quickly expanding healthcare markets in the region are in addition growing at an annual rate of some 12%, which is more than double the growth rate for the sector worldwide, the firm adds.
